AbbVie drops further on below-expected third-qtr revenue

31 October 2016

The share price of US drugmaker AbbVie (NYSE: ABBV) was in decline again on Monday morning after revenue levels in its third quarter 2016 results fell below analysts’ predictions.

AbbVie shares fell in value by more than 6% to $57.59 on Friday, and they had slipped by a further 2% to $56.40 by midday on Monday.

Analysts surveyed by financial data provider FactSet had anticipated the Chicago-based firm to report revenue for the quarter of $6.56 billion, but the reported figure was $6.43 billion. This is a 8.2% rise compared to the same period in 2015, and it is a similar story when AbbVie’s flagship arthritis treatment Humira (adalimumab), the world’s best-selling drug, is considered alone.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK